End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.35 USD | 0.00% | -1.84% | +16.29% |
Apr. 30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Financials (USD)
Sales 2024 * | 353M | Sales 2025 * | 606M | Capitalization | 3.77B |
---|---|---|---|---|---|
Net income 2024 * | -149M | Net income 2025 * | 30M | EV / Sales 2024 * | 14.8 x |
Net Debt 2024 * | 1.46B | Net Debt 2025 * | 1.28B | EV / Sales 2025 * | 8.33 x |
P/E ratio 2024 * |
-22.6
x | P/E ratio 2025 * |
130
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.2% |
Latest transcript on Alvotech
1 week | -1.84% | ||
Current month | -7.93% | ||
1 month | +4.87% | ||
3 months | -15.61% | ||
6 months | +47.84% | ||
Current year | +16.29% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 69 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 12-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 13.5 | +1.12% | 75,854 |
24-05-15 | 13.35 | 0.00% | 59,441 |
24-05-14 | 13.35 | +0.45% | 76,613 |
24-05-13 | 13.29 | -0.60% | 75,109 |
24-05-10 | 13.37 | -1.69% | 55,205 |
End-of-day quote Nasdaq, May 14, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.29% | 3.77B | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.79% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- ALVO Stock